Phio Pharmaceuticals Corp. PHIOW 深 沪
等待开盘 03-26 09:30:00 美东时间
0.0232
0.000
0.00%
华盛通- 最 高--
- 今 开--
- 成交量 0股
- 最 低 --
- 昨 收 0.0232
- 总市值 10.63万
- 52周最高 1.16
- 市盈率 静 --
- 换手率 0.00%
- 52周最低 0.006
- 委 比 0.00%
- 总股本 458.09万
- 历史最高 1.16
- 量 比 0
- 振 幅 0.00%
- 历史最低 0.006
- 每 手 1
- 风险率 0.00%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Phio Pharmaceuticals reports 65% pathological response rate in Phase 1b trial of PH-762 for cutaneous squamous cell carcinoma
Phio Pharmaceuticals reports 65% pathological response rate in Phase 1b trial of PH-762 for cutaneous squamous cell carcinoma Phio said Phase 1b results from its escalating-dose study of intratumoral PH-762 (NCT 06014086) in cutaneous squamous cell carcinoma, melanoma and Merkel cell carcinoma will
03-23 19:04
Phio Pharmaceuticals to Present at Renmark Financial Communications Live Virtual Non-Deal Roadshow Series
Phio Pharmaceuticals to Present at Renmark Financial Communications Live Virtual Non-Deal Roadshow Series Phio Pharmaceuticals Corp. will participate in Renmark Financial Communications’ live Virtual Non-Deal Roadshow Series with a live presentation and Q&A on Monday, March 9, 2026 at 10:00 a.m. EDT
03-05 20:03
Phio Pharmaceuticals boosts CEO Bitterman severance and target bonus terms
Phio Pharmaceuticals boosts CEO Bitterman severance and target bonus terms Phio Pharmaceuticals Corp. amended CEO Robert J. Bitterman’s employment agreement. The update raises his annual target bonus opportunity to 50% of base salary (from 40%) and provides 12 months of base-salary severance if he i
02-19 05:01
Cancer Biotech Phio Pharmaceuticals Stock Surges As Trial Shows Tumor Clearance At Highest Dose In Skin Cancer Patients
Phio Pharmaceuticals shares rise after Phase 1b data shows strong safety and tumor clearance for its PH-762 skin cancer drug, with FDA talks planned in 2026.
02-11 00:12
BUZZ-U.S. STOCKS ON THE MOVE-Zimmer Biomet, Datadog, Ecolab
BUZZ-U.S. STOCKS ON THE MOVE-Zimmer Biomet, Datadog, Ecolab Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: https://refini.tv/3LI4BU7 The Morning News Call newsletter: https://refini.tv/3dKUyB8 The S&P 500 and the Nasdaq edged lower on Tuesday, bogged down by decline
02-10 23:41
Phio Pharmaceuticals Reports Positive PH-762 Phase 1b Safety Results
Phio Pharmaceuticals ( ($PHIO) ) has shared an announcement. On February 10, 20...
02-10 20:59
Phio Pharmaceuticals Reports Positive Safety and Efficacy Results for PH-762 in Phase 1b Skin Cancer Trial
Phio Pharmaceuticals Reports Positive Safety and Efficacy Results for PH-762 in Phase 1b Skin Cancer Trial Phio Pharmaceuticals Corp. has announced the completion of a safety review by the Safety Monitoring Committee (SMC) for its lead clinical candidate, PH-762, in a Phase 1b skin cancer trial. The
02-10 20:03
Phio Pharmaceuticals meldet erfolgreiche Sicherheitsdaten für PH-762 in Phase-1b-Hautkrebsstudie
Phio Pharmaceuticals meldet erfolgreiche Sicherheitsdaten für PH-762 in Phase-1b-Hautkrebsstudie Phio Pharmaceuticals Corp. hat bekannt gegeben, dass der Sicherheitsüberwachungsausschuss (SMC) die geplante Sicherheitsüberprüfung für alle mit dem Wirkstoff PH-762 behandelten Patienten in einer Phase-
02-10 20:03
Phio Pharmaceuticals Data From Phase 1b Dose Escalation Clinical Study Shows 14 Participants To Be Pathologic Responders, Including 10 With 100% Clearance
Phio Pharmaceuticals Corp. (NASDAQ:PHIO) is a clinical-stage siRNA biopharmaceutical company developing therapeutics using its proprietary INTASYL® gene silencing technology to eliminate cancer. Phio announced
01-20 22:35
Phio Advances PH-762 With FDA-Backed Toxicology Study
Phio Pharmaceuticals ( ($PHIO) ) has provided an announcement. On December 23, ...
2025-12-23 22:15
